Publication date: Jul 25, 2024

This study aimed to evaluate the effectiveness of SARS-CoV-2 mRNA vaccines in preventing infection and hospitalization among healthcare workers (HCWs) in the Valencian Community (Spain), considering vaccination timing, dose number, and predominant variant. A test-negative case-control design estimated vaccine effectiveness against symptomatic disease and hospitalization due to SARS-CoV-2. HCWs who underwent PCR or antigen testing for SARS-CoV-2 from January 2021 to March 2022 were included. Cases had a positive diagnostic test, while controls had negative tests. Adjusted vaccine effectiveness (aVE) was calculated using the formula: aVE = (1 – Odds ratio) cD7 100. During the Delta variant’s predominance, aVE against infection within 12-120 days post-second dose was 64. 8 % (BNT162b2) and 59. 4 % (mRNA-1273), declining to 21. 2 % and 42. 2 %, respectively, after 120 days. For the Omicron variant, aVE within 12-120 days post-second dose was 61. 1 % (BNT162b2) and 85. 1 % (mRNA-1273), decreasing to 36. 7 % and 24. 9 %, respectively, after 120 days. After a booster dose of mRNA-1273, aVE was 64. 0 % (BNT162b2 recipients) and 65. 9 % (initial mRNA-1273 recipients). Regardless of variant, aVE for hospitalization prevention after 2 doses was 87. 0 % (BNT162b2) and 89. 0 % (mRNA-1273). The administration of two doses of Moderna-mRNA-1273 against SARS-CoV-2 in HCWs proved to be highly effective in preventing infections and hospitalizations in the first 120 days after the second dose during the predominance of the Omicron variant. The decline in VE after 120 days since the administration of the second dose was significantly restored by the booster dose administration. This increase in VE was greater for the Pfizer vaccine. COVID-19 hospitalization prevention remained stable with both mRNA vaccines throughout the study period.

Open Access PDF

Semantics

Original Article